The Food and Drug Administration approved Pharmacyclics Inc.'s (Nasdaq: PCYC) chronic lymphocytic leukemia treatment IMBRUVICA sending the stock price soaring $16.25 to close at $124.75.
FDA approves Pharmacyclics' IMBRUVICA
July 29, 2014 at 18:17 PM EDT
